Cantor Fitzgerald Comments on MiMedx Group FY2025 Earnings

MiMedx Group, Inc. (NASDAQ:MDXG) – Equities research analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for shares of MiMedx Group in a research note issued on Wednesday, April 16th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings per share of $0.30 for the year, down from their prior forecast of $0.31. Cantor Fitzgerald currently has a “Overweight” rating and a $13.00 price target on the stock. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The company had revenue of $92.91 million for the quarter, compared to analysts’ expectations of $89.42 million.

Separately, StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Wednesday.

MiMedx Group Stock Up 0.7 %

Shares of MiMedx Group stock opened at $6.68 on Thursday. MiMedx Group has a 1-year low of $5.47 and a 1-year high of $10.14. The company has a market capitalization of $983.67 million, a P/E ratio of 12.14 and a beta of 1.74. The business’s fifty day moving average price is $7.72 and its two-hundred day moving average price is $8.00. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53.

Institutional Trading of MiMedx Group

Several institutional investors and hedge funds have recently bought and sold shares of MDXG. First Light Asset Management LLC purchased a new position in shares of MiMedx Group in the fourth quarter worth approximately $32,168,000. Norges Bank purchased a new stake in shares of MiMedx Group in the 4th quarter valued at approximately $4,020,000. JPMorgan Chase & Co. boosted its stake in MiMedx Group by 133.1% in the 4th quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company’s stock worth $6,668,000 after purchasing an additional 395,739 shares during the period. Meros Investment Management LP purchased a new position in MiMedx Group during the 4th quarter worth approximately $3,801,000. Finally, Arrowstreet Capital Limited Partnership grew its position in MiMedx Group by 484.2% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company’s stock worth $3,487,000 after purchasing an additional 300,433 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

Insider Transactions at MiMedx Group

In other MiMedx Group news, CAO William Frank Iv Hulse sold 81,446 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $7.80, for a total value of $635,278.80. Following the transaction, the chief accounting officer now owns 494,774 shares of the company’s stock, valued at approximately $3,859,237.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the sale, the insider now directly owns 310,836 shares of the company’s stock, valued at approximately $2,452,496.04. This represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 144,018 shares of company stock valued at $1,130,312. Corporate insiders own 1.30% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.